Cilostazol Treatment of Claudication in Diabetic Patients

Summary Objective: To compare the efficacy and safety of cilostazol in diabetic and non-diabetic patients from eight (six placebo- and two active-controlled) randomised, double-blind phase III trials. Design: We only included patients from the trial data set receiving cilostazol 100 mg twice daily (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current medical research and opinion 2002, Vol.18 (8), p.479-487
Hauptverfasser:	Rendell, Marc, Cariski, Alan T., Hittel, Norbert, Zhang, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Absolute claudication distance Adult Biological and medical sciences Cardiovascular system Cilostazol Diabetes Diabetes Complications Diabetes Mellitus - physiopathology Double-Blind Method Female Humans Intermittent claudication Intermittent Claudication - complications Intermittent Claudication - drug therapy Male Medical sciences Middle Aged Peripheral arterial disease Pharmacology. Drug treatments Placebos Tetrazoles - administration & dosage Tetrazoles - therapeutic use Treatment Outcome Vasodilator Agents - administration & dosage Vasodilator Agents - therapeutic use Vasodilator agents. Cerebral vasodilators
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Objective: To compare the efficacy and safety of cilostazol in diabetic and non-diabetic patients from eight (six placebo- and two active-controlled) randomised, double-blind phase III trials. Design: We only included patients from the trial data set receiving cilostazol 100 mg twice daily (216 diabetic/599 non-diabetic) or placebo (220/616). Efficacy was measured by absolute claudication distance (ACD), using standard treadmill exercise protocols. Results: Among diabetic and non-diabetic patients, cilostazol was superior to placebo (estimated treatment effect 1.15, 95% confidence interval, 1.05-1.25, p = 0.001; and 1.24,1.18-1.31, p
ISSN:	0300-7995 1473-4877
DOI:	10.1185/030079902125001245